Xun, Xu,,
Liang, Yuan,
Gareev, Ilgiz,
Liang, Yanchao,
Liu, Rui,
Wang, Ning,
Yang, Guang (2023) Glioma is the most frequent type of malignant tumor in the central nervous system, accounting
MENG, X.,
DUAN, C.,
PANG, H.,
CHEN, Q.,
HAN, B.,
MAGAFUROV, D.A.,
WU, P.,
LI, Z.,
ZHAO, S.,
WANG, R.,
LIN, L.,
JIANG, C.,
CAI, J.,
ZHA, C. (2019) , progression, and therapeutic resistance. However, the involvement of DDR alterations in
glioma malignancy
Lu, Enzhou,
Gareev, Ilgiz,
Yuan, Chao,
Liang, Yanchao,
Sun, Jingxian,
Chen, Xin,
Beylerli, Ozal,
Sufianov, Albert,
Zhao, Shiguang,
Yang, Guang (2022) Gliomas are the most common and malignant primary tumors of the central nervous system (CNS
WANG, K.,
LIU, H.,
LIU, J.,
WANG, X.,
TENG, L.,
ZHANG, J.,
CHEN, X.,
WANG, N.,
ZHONG, Y.,
HOU, X.,
JIANG, H.,
ZHANG, X.,
ZHAO, S.,
LIU, Y.,
YAO, Y.,
WANG, J.,
QU, Y.,
PENG, F.,
BEYLERLI, O.,
LIAO, X. (2019) of
glioma cell metabolism reprogramming since the significance of IDH1 was confirmed in
glioma. However
Gliomas are the most common and fatal primary brain tumor in adults.
Gliomas are highly invasive
Wu, JN,
Al-Zahrani, A,
Beylerli, O,
Sufianov, R,
Talybov, R,
Meshcheryakova, S,
Sufianova, G,
Gareev, I,
Sufianov, A (2022) important roles in the oncogenesis and progression of
gliomas including high-grade
gliomas. However
Sun, J.X.,
Sun, Z.Y.,
Gareev, I,
Yan, T,
Chen, X,
Ahmad, A,
Zhang, D.M.,
Zhao, B.X.,
Beylerli, O.,
Yang, G.,
Zhao, S.G. (2021) on evaluation of exosomal miR-2276-5p in plasma as a diagnostic and prognostic biomarker for
glioma.
Methods
CHEN, Q.,
HAN, B.,
MENG, X.,
DUAN, C.,
YANG, C.,
WU, Z.,
MAGAFUROV, D.,
ZHAO, S.,
JIANG, C.,
CAI, J.,
SAFIN, S (2019) signatures to identify
glioma microenvironmental genes. The functional enrichment analysis such as ss
Han, Dayong,
Teng, Lei,
Wang, Xiaoxiong,
Zhen, Yunbo,
Chen, Xiaofeng,
Yang, Mingchun,
Gao, Ming,
Yang, Guang,
Han, Mingyang,
Wang, Ligang,
Xu, Jiajun,
Li, Yue,
Shumadalova, Alina,
Zhao, Shiguang (2022) Background:
Glioma is the most common primary brain tumor in adults with poor prognosis. The
gliomaMENG, X.,
DUAN, C.,
PANG, H.,
CHEN, Q.,
HAN, B.,
MAGAFUROV, D.A.,
WU, P.,
LI, Z.,
ZHAO, S.,
WANG, R.,
LIN, L.,
JIANG, C.,
CAI, J.,
ZHA, C. (2019) , progression, and
therapeutic resistance. However, the involvement of DDR alterations in
glioma malignancy
